Lilly’s next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz – FierceBiotech

by

  1. Lilly’s next obesity drug just cut an average of 58 pounds—prompting an all-out phase 3 blitz FierceBiotech
  2. A new weight-loss drug dubbed the ‘triple G’ could be stronger than Ozempic, Wegovy, and Mounjaro — and as powerful as bariatric surgery Yahoo Life
  3. Eli Lilly (LLY) Weight-Loss Shot Gives Company’s Strongest Results in Trial Bloomberg
  4. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial The Lancet
  5. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM nejm.org
  6. View Full Coverage on Google News

Read original article here

Leave a Comment